Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?

European Journal of Dermatology

Volumn 24, Issue 2, 2014, Pages 265-267

  Baroudjian, Barouyr ^a   Boussemart, Lise ^a   Routier, Emilie ^a   Dréno, Brigitte ^b   Tao, Yungan ^a   Deutsch, Eric ^a   Blanchard, Pierre ^a   Dhermain, Frédéric ^a   Vilcot, Laurence ^a   Vagner, Stephan ^a   Eggermont, Alexander ^a   Mateus, Christine ^a   Robert, Caroline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CD31 ANTIGEN; CD34 ANTIGEN; DOCETAXEL; PACLITAXEL; PAZOPANIB; PLACEBO; TAXANE DERIVATIVE; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; RADIOSENSITIZING AGENT; SULFONAMIDE; VEMURAFENIB;

ADULT; ANGIOSARCOMA; ARTICLE; BLEEDING; CANCER RADIOTHERAPY; CASE REPORT; DIARRHEA; DRUG SUBSTITUTION; FATIGUE; FEMALE; HAIR DISCOLORATION; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MIDDLE AGED; PARTIAL MASTECTOMY; PROGRESSION FREE SURVIVAL; SOFT TISSUE SARCOMA; TUMOR RECURRENCE; WEIGHT REDUCTION; GENETICS; MALE; MELANOMA; MULTIMODALITY CANCER THERAPY; REMISSION; SKIN NEOPLASMS; VERY ELDERLY;

ADULT; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; HUMANS; INDOLES; MALE; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; RADIATION-SENSITIZING AGENTS; REMISSION INDUCTION; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84901272172     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2014.2300     Document Type: Article

References (10)

1. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30: 2522-9.
2. Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011; 364: 2507-16.
3. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011; 98: 394-9.
4. Warenius HM, Jones M, Gorman T, et al. Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. Br J Cancer 2000; 83: 1084-95.
5. Carter S, Auer KL, Reardon DB, et al. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 1998; 16: 2787-96.
6. Boussemart L, Boivin C, Claveau J, et al. Vemurafenib and Radiosensitization. JAMA Dermatol 2013; 10: 1001.
7. Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R. Serious Skin Toxicity With the Combination of BRAF Inhibitors and Radiotherapy. J Clin Oncol 2013; 31: e220-2.
8. Ducassou A, David I, Delannes M, Chevreau C, Sibaud V. [Radiosensitization induced by vemurafenib]. Cancer Radiother 2013; 17: 304-7.
9. Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013; 10: 31.
10. Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 2013; 23: 175-8.